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Introduction

Immunology is rooted in the discoveries of Pasteur and Jenner that
contact with infectious agents could confer protection.

Subsequently,

attempts to explain this immunity centered upon the humoral factors
involved until Chase and Landsteiner showed that delayed hypersensi¬
tivity could be transferred passively with peritoneal exudate cells.
With the discovery that the small lymphocyte was involved in delayed
hypersensitivity reactions, a new era of investigation was inaugurated.
In the past fifteen years, scientists have distinguished at least
two types of peripheral lymphocytes - those cells which enter the
peripheral tissue via the thymus (the T cell), and those cells which
do not (the bone marrow derived lymphocyte or B cell).

These two

cell populations are indistinguishable by conventional morphological
techniques, but they are separable functionally.

The B cell is the

precursor of the antibody producing plasma cell and thus is directly
involved in humoral immunity.

The T cell plays a major roll in cellular

immunity and recent evidence indicates that it also is involved in re¬
gulating certain B cell humoral responses.
Because of its importance in the immune system, the T cell has
become a subject of intense investigation.

It is the purpose of this

thesis to review the work in this area and to present further evidence
concerning the role of the T cell in tumor allograft rejection.

2

Review of the Literature

In mammals the thymus consists of a paired endodermal structure
derived from the third and fourth brachial clefts.

It increases in

size until puberty when it regresses in relation to body development.^
Histologically the organ is composed of a distinct medullary and cortical
regions. 2
The function of the thymus remained an enigma until it was shown
that thymectomized neonatal rodents responded poorly to certain antigens,
particularly those stimulating delayed hypersensitivity reactions.

3-11

A marked deficiency of lymphocytes was noted in the peripheral blood,
lymph nodes, and spleen.

The same immunologic and morphologic defi¬

ciency was noted when adult mice were thymectomized and given sublethal
irradiation.

12

This immune deficiency was unchanged following recon-

stitution with cells from the bone marrow of syngeneic animals.

13

However, immunologic competence could be restored by implanting syn¬
geneic thymuses.14“17

Szenberg and Warner, and subsequently Cooper,

showed that in the chicken, thymectomy was associated with an impair¬
ment of the capacity to reject skin grafts, but not with defects in
I O

antibody production.

I Q

’

Thus, the thymus was established as a major

factor in the development of peripheral lymphoid tissue and in certain
forms of the immune response.
Many believed that the thymus exerted its influence by humoral
factors.

The famous millipore experiments of Osoba and others confirmed

1

*

3

this belief.

20—21

Another line of evidence, however, established that

cells do pass through the thymus.

When thymus tissue bearing a chromo¬

some marker (T6) was implanted in thymectomized, tolerant hosts, donor
no

cells were found in the peripheral lymphoid tissue of the host.

n s

“ 0

The labeled cells localized in specific areas of the peripheral tissue.
Large numbers were found in the thoracic duct.

The cells were present

in the cortex and paracortical areas of lymph nodes, and in the periarteriolar lymphocyte sheaths of the spleen.

These were the same

areas previous investigators had noted to be depleted in neonatally
27—2 8
thymectomized animals.“

This type of study involves the disruption

of the donor thymic tissue which might allow these cells to escape,
thus giving artifactual results.

However, another series of experi¬

ments in which newborn rodent thymuses were labeled in situ with tritiated thymidine confirmed the results of the T6 investigations.

29

The fate of the peripheral thymus-derived lymphocytes was explored
by Miller and Mitchell.

Radioactively tagged T cells were injected

into heavily irradiated syngeneic hosts with sheep RBC.

Some of the

donor cells in the host spleen responded to the antigenic stimulus
by forming large, pyroninophilic cells which then gave rise to small
lymphocytes.

30-31

These small lymphocytes did not produce any de-

tectable antibody to the sheep RBC

and were traced to the paracortical

areas of lymph nodes and the periarteriolar lymphocyte sheaths in the
spleens of the host animals.

On the basis of this evidence, these

investigators suggested that the recirculating small lymphocyte pool

£:

-
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might be the progeny of thymus cells which had been exposed to antigens
in the past.
Our present knowledge of the specific actions of T cells is partly
derived from studies on in vitro killing of allogeneic cells and from
the studies of the graft-versus-host (GVH) reactions in laboratory
animals.

Simonsen and Billingham first described a syndrome of spleno¬

megaly, hepatomegaly, thymic hyperplasia and runting (first called the
"runting syndrome" then renamed the GVH reaction) when adult allogeneic
spleen cells were injected into neonatal mice.

33

The donor cell reactions

only occurred if the recipients were first rendered tolerant.

The pro¬

cedures necessary to induce tolerance also limited the ability of in¬
vestigators to study the donor-recipient cell interactions.

In 1962,

Simonsen presented a new animal model system for studying the GVH reaction
In this system, two strains, each homozygous at the H2 histocompatibility
loci, are crossed such that the

has one set of loci from each parent.

The Fy is tolerant to both parents’ cells while each parent can recognize
the H2 antigen of the other present in the F-^ and mount a reaction
against it.

In this system, the F-^ does not have to be immunologically

depleted in order to establish a unidirectional reaction of the donor
cells rejecting

the host.

Early investigations demonstrated that the GVH reaction followed
the lines of a classic immune reaction.

If the donor was made tolerant

to the recipient’s antigens prior to injection, the GVH reaction could be
modified or completely abrogated as measured by the host’s splenomegaly.

35

34
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If the donor was immunized with the host’s cells prior to injection,
the reaction could be magnified.^ ^

Billingham and Silver demonstrated

that the small lymphocyte in the peripheral blood could cause the GVH
O O

reaction.

When Davies and Doak showed that cells from neonatally

thymectomized animals could not cause the GVH reaction, the role of
the thymus in cellular immune reactions was established and the GVH
system became a prime model for further investigation.

Elkins

showed that the kidney in the GVH reaction had the same pathological
picture as the kidney in allograft rejection.

40

He also demonstrated

that the donor cells were specifically activated by the H2 antigenic
difference of the host.
More recently, investigators have shown that some type of cellular
interactions occur between subpopulations of donor cells in the GVH
reaction.

Cantor and Asofsky have demonstrated that different sources

of mouse lymphoid tissue could act synergistically in the GVH reaction.
In these experiments, all the cells which could act synergistically
had to be specifically reactive against the host cells.

Work pub¬

lished concurrently by Hilgaard and Gershon and Barchilon have demon¬
strated synergism between combinations of parental T cells and parental
and Fy bone marrow derived cells (BMD cells).5 ^

In these experi¬

ments, synergy occurred between specifically activated immune cells
(the T cell) and non-specific, nonimmune BMD cells.

Liebhaber has

suggested that these results may not be contradictory.

He postulated

41

—
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a three cell interaction involving two subpopulations of T cells, each
specifically activated, which synergize and then affect non-specific
BMD cells.42
A different line of evidence supports the concept of cooperation
between T cells and other immunologically active cells.

Clamaan measured

the hemolysin response to sheep RBC in lethally irradiated mice after
AO

injecting various combinations of T cells and B cells.

In these

experiments, either B cells mixed with T cells or spleen cells mixed
with T cells gave a significantly greater response than the sum of the
individual responses.

Davies and his colleagues showed that the T cell

did not produce antibody, but it greatly increased the ability of B cells
to do so.44

Several investigators have shown that the immunologic speci¬

ficity in these cellular interactions rests with the B cell.4^-4^

Other

workers have shown that in those systems which involve T cells in antibody production, tolerance rests with the T cell.

48

Cooperation between T cells and BMD cells occurs in other immune
responses, as the mouse foot pad response to methylated serum albumin.

49

In this experiment, the investigators demonstrated that the T cell was
the immunologically specific cell while the BMD cell was a non-specific
effector cell.

Other investigators have confirmed this relationship

in different animal model systems.The BMD cell involved in
these reactions is probably not the antibody producing B cell.

Recent

evidence suggests that the macrophage is playing the role of the nonro

specific effector cell in these cellular mediated immune reactions.

£'

7

The complex interactions involving T cells outlined in the preceeding pages may actually represent the actions of more than one T
cell population.

Re if and Allen were among the first to note that

the T cell membrane carried an antigenic marker, the theta antigen.

53

Other investigators have shown that the theta antigen is specific for
lymphocytes which have passed through the thymus.

54

Specific anti¬

theta antibody and compliment can lyse cells carrying the antigen.
Another antigenic marker, the T1 antigen, was found among the cells
from the thymic cortex.

55

The thymus cells of the medulla and cortex

can also be separated by their sensitivity to cortisone.

Dougherty

noted that animals treated with corticosteroids lost nearly all the
cells in the thymic cortex while the cells in the medulla appeared to
be unaffected (the medullary thymocytes have been named cortisoneresistant thymus cells).56

The T1 antigen is specific for those cells

which are sensitive to cortisone.

57

Several lines of investigation have demonstrated that the cortisoneresistant T cells are immunologically much more active than the cortical
thymocytes.

Warner has shown that the cortisone-resistant T cell is

much more active than whole thymus cells in damaging the chick chorio¬
allantoic membrane.The phytohemagglutinin responding cells in the
pig thymus were shown to be cortisone resistant.59

Blomgren and

Andersson have done a series of experiments in which the cortisoneresistant cell was shown to be ten times more effective per cell than
whole thymus cells in inducing splenomegaly in the GVH reaction and in

.

interactions of B cells to T dependent antigens,

The experiments

which have separated these two thymus cell populations indicate that
the cortisone-resistant T cell is a highly immunocompetent cell in¬
volved in all the previously described T cell reactions.

The role of

the cortisone-sensitive cell, which comprises ninety-five per cent
of the thymocyte population,has remained an enigma until recent in¬
vestigations by Gershon's group.

They have shown that the cortisone-

sensitive cell can stimulate or suppress the response of the cortisoneresistant T cells as measured by the DNA synthesis of spleen cells in
the GVH reaction.^
Pharmacologic doses of cortisone could produce an artifactual
division inlhe thymus population, though this seems unlikely in the
presence of such diverse experimental observations supporting separation
of the populations both antigenically and functionally.
Another line of evidence also suggests the presence of subpopula¬
tions of T cells with regulator and effector functions.

Lance and Taub

noted that anti-lymphocyte serum (ALS) in low doses specifically eli¬
minated a population of T cells which were recirculating, or found in
lymph nodes, but did not affect T cells in the spleen or thymus.
Several investigators have shown that decreasing the number of recir¬
culating T cells of the host greatly decreases the GVH activity. ^5-o(j
Asofsky’s group has recently done a series of experiments in which
cells from the peripheral blood and cells from the thymus and spleen
were used to induce a GVH reaction in

hosts.

In these experiments,

*
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two cell populations, each immunologically specific, acted synergistically.
Both cell populations were composed of T cells, as discussed previously.^
They have demonstrated that the

population of cells located in the

thymus and spleen, which are resistant to low doses of ALS, are the
precursors of the cell which "inflicts immunologic injury."

The T2

cell found in the blood and peripheral lymph nodes, which is very sen¬
sitive to low doses of ALS, acts to amplify the activity of the Tj_
cell.

As described previously, many investigators have shown that

T cells can act as "helper cells" to increase the antibody production
of B cells.

Recently Miller’s group has demonstrated that ALS in low

doses can destroy the T helper cells as measured by the B cell response
to certain antigens.^9

These results are particularly important as

they suggest that humoral and cellular mediated immune responses may
be under the control of a single cell population, the T2 cell.
There is no evidence that relates the Ty and T2 populations to
cortisone-sensitive and resistant T cells.

These groups of T cells

seem to be related functionally, but any conclusions must await further
investigations.
functions exist.

Clearly subpopulations of T cells which have different
Experiments have been discussed which demonstrate

that T cells can amplify both humoral and cellular mediated responses.
A body of evidence is now accumulating which indicates that T cells
also can suppress the immune response.
Several investigators have demonstrated that an animal tolerant
to an antigen does have B cells capable of responding to the antigen.

70-71

c

r
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McCullagh has shown that allogeneic T cells injected into a rat tolerant
to an antigen permits the animal to respond, while syngeneic T cells
have no effect.

Work by Gershon's group indicates that the T cell

is required for both the induction of tolerance and immunity for in¬
dependent antigens (Antigens for which T cells act as helper cells to
no

boost antibody production).

°

They have also demonstrated that anti¬

genic competition, the phenomenon in which an immune response induced
to one antigen may inhibit the response to another unrelated antigen,
is also dependent on T cells.

Recently Tada and his associates

have presented evidence that the suppressor effects of T cells are
immunologically specific.

The antibody to a haptene conjugated

to one carrier was suppressed by the addition of T cells from a syn¬
geneic animal hyperimmunized against the haptene-carrier combination,
but antibody to the haptene conjugated to a different carrier was un¬
affected.

Baker and his colleagues have published a series of papers

concerning the antibody response to pneumococcal polysaccharide type
1A

III (S III), another antigen described as T cell independent.

They

have shown that the administration of low doses of ALS causes an increase
in the antibody against S III due to an increase in antibody producing
cells.

77

They suggested that this increase was due to the elimination

of a suppressor T cell.

78

In the past, different workers have noted that splenectomized
animals can elicit a greater immune response against a tumor graft than
whole animals.

In light of the localization of the T-^ cell to the

')
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spleen,some investigators have reinterpreted this data to be another
example of T cell suppression.

Field has presented evidence that F]_

rats become refractory to the induction of a GVH reaction after having
had a GVH reaction previously.

Field suggested that a humoral factor

mediated this suppressed immunologic state.

80

Recently Michael and

Veit have demonstrated an inhibitory factor present in the serum of
mice which specifically suppresses the response of T cells to T-dependent
antigens.

Though no one has yet shown that T cells produce a suppre¬

ssor substance, the evidence indicates that either the T cell itself
produces such a substance or it is associated with another unidentified
cell which does.
Thus the experiments on T cell suppression include both humoral
and cellular mediated immune responses, like the data on T cell ampli¬
fication.

It is particularly noteworthy that the data regarding the

effect of low doses of ALS on antibody production by Baker suggests
that the T2 cell, which Asofsky has described as an amplifier cell,
also has suppressor function.

This could be explained by either the

presence of other subgroups with opposite effects within the T2 group,
or by the hypothesis that the T2 cell effects the regulation of an
immune response according to the antigen and the circumstances surround¬
ing the stimulus, as Gershon has suggested.^
Much of the evidence for the thymus cell reactions discussed have
come from studying antibody production or the GVH reaction.

Many

other model systems have been developed to examine in vitro and in vivo

12

OO

cellular immune reactions.

Some of these systems employ various com¬

binations of cells and sera to kill allogeneic or xenogeneic cells.
The endpoint measured frequently is the release of some labeled particle
which has been incorporated in the target cell.

Several different

lines of investigation have been pursued, each demonstrating a different
cellular interaction necessary to kill a target cell.
Lonai and Feldman have used a system involving rat donor cells
and mouse fibroblasts as the target cell to demonstrate that T and
BMD cells act synergistically to lyse target cells.

84

They have pre¬

sented evidence that the T cell is the immunologically specific cell
in this system.^

Alexander’s group, working in an allogeneic in

vitro system, have shown that T cells themselves have little cyto¬
toxicity.

In this system the T cells produce a factor that induces

cytotoxic cells from the bone marrow.^

MacLennan has experimental

evidence along a similar line that demonstrates that the effector cell
is triggered by an IgG complexed with a target cell antigen.

87 — 88

Other investigators have shown that the macrophage is involved in
lysing allogeneic cells.

Granger and Weiser were among the first to

show that macrophages lyse cells by intimate cell contact, not by
phagocytosis.

89

Evans and Alexander have shown that macrophages are

immuno logic ally specific effector cells.

They have demonstrated

that media from spleen cells immunized against a specific target cell
contains a factor, "macrophage arming factor," which renders macrophages
no

specifically cytotoxic for the target cells.

.
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Other investigators have used different cell populations from
spleens and lymph nodes to demonstrate that the immunized effector cells
do not release a toxin.9o-9^

Moreover,

if one removes the macrophage

from immunized peritoneal exudate cells, target cell lysis is unaffected.95-1,5
Brunner, Nordin, and Gerottini have done a series of experiments to
help clarify the confusing array of data in this area.

They have

shown that spleen cells from mice immunized with alloantigens contain
immune lymphocytes and alloantibody-producing cells (PFC).'

If this

heterogeneous population is treated with anti-theta and compliment
no in vitro target cell lysis occurs, but the number of PFC is unaffected.9®-99
When they treated peritoneal cells from mice immunized against allogeneic
cells with anti-theta serum and compliment, cytotoxicity was abolished.
But when these cells were treated with anti-macrophage serum and compli¬
ment no effect was noted on target cell lysis in vitro.
The function of cells in vitro and in vivo may not necessarily
be the same.

Freedman, Cerottini, and Brunner therefore examined

these same questions in a functional in vivo animal model which they
developed.

They showed that allogeneic tumor cells were rejected

by immune specific spleen cells which were derived from T cells.

They

could not demonstrate the presence of any mediators involved in the
actions of the immune T cells.
of B cells and macrophage.

Moreover, the T cells acted independently

14

Summary

Miller and his colleagues were among the first to demonstrate
that the thymus gland played a central role in the development of peri¬
pheral lymphoid tissue and was essential for the function of the immune
system. 102-103

^he Specific role of the T cell in the body’s defense

is slowly being delineated.

When Davies established that cells from

a thymectomized animal could not cause a GVH reaction,

it became

clear that the T cell was a principle participant in cellular mediated
immune responses.

Several different types of experimental studies

have shown that subpopulations of T cells with different functions
exist.
Asofsky and Cantor have presented experiments in which

cells,

which are insensitive to low doses of ALS and are located in the thymus
and spleen, effect immunologic injury, while the T2 cell, which rapidly
recirculates and is very sensitive to low doses of ALS, can amplify
the effect of the

cell.

Gershon's group have also demonstrated

that one subpopulation of T cells, the cortisone sensitive cells, can
regulate the effect of a second T cell population, the cortisone-resis,
,
106
tant cells.
Interactions also occur between T and B cells in which the T cell
acts to suppress or amplify the antibody producing B cells.07-108
Investigators have also shown that T cells interact with T cells as
well as with BMD cells (which are probably macrophage) in cellular

V.
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immune reactions. -*-09-110

Thus it is clear that the T cell not only

plays a major role in effecting immunologic injury in cellular mediated
immune responses, it also is involved in regulating the T cell injury
as well as antibody production by B cells.

16

Experimental Section

Freedman, Cerottini, and Brunner have demonstrated that in vivo
the T-derived sensitized cell is able, by itself, to bring about the
rejection of allogeneic tumor cells.

This reaction does not require

antibody, B cells, or macrophages and cannot be accomplished by anti¬
body producing B cells and macrophages in the absence of specifically
sensitized T-derived lymphocytes.

In this system C3H(H2K) thymus

cells were sensitized to H2 antigens by injection into lethally irradi¬
ated (850 rads) allogeneic hosts, the DBA2(H2D), thus establishing a
GVH reaction.

The sensitized T cells were then harvested from the

allogeneic hosts’ spleens and injected into C3H(H2K) recipients at the
same time as ascites tumor cells (P-815-X2) carrying the same H2
antigen as the DBi^I^D) (see figure I).

The investigators showed

that the ascites tumor cell growth during the first four days after
injection into the allogeneic host was the same as in the syngeneic
host unless sensitized T cells were also added.

Thus, this system

allowed the investigators to examine the effects of sensitized T cells
on allogeneic tumor cell growth in a syngeneic animal.
In this thesis the same animal model was used to determine whether
T cell interactions also occurred in tumor allograft rejection as has
been described in other cellular mediated reactions.

112

The animal

model developed by Freedman et al allows one to examine modifiers of
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T cell activity in both the afferent limb of the immune response, or the
stage when sensitized T cells are formed, and the efferent limb, or
the stage when the sensitized T cells effect tumor killing.

In the present

experiments, the afferent limb was investigated by examining the relation¬
ship between the dose of thymus cells required to produce sensitized
T cells and the degree of tumor suppression.

A similar series of

experiments were undertaken to evaluate the efferent limb by examining
the relationship between the dose of sensitized T cells and the degree
of tumor suppression.

To see whether subpopulations of T cells exerted

a regulatory influence upon each other, cortisone-resistant cells were
compared to whole thymus cell populations as to their effect on tumor
growth.

Experiments were also done to determine whether the syngeneic

host’s cells interacted with the sensitized T cells in the tumor rejection
process.

C. .

' ;
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Materials and Methods

Mice:

All mice were males from Jackson Laboratory, Bar Harbor, Maine.

C3H thymocyte donors were five weeks old.
were seven or eight weeks old.

CDF^ and C3H recipients

All mice were rested one week in the

laboratory before use.
Irradiation:

Recipient mice received 850 rads (mid-axial dose) from

a Siemens Stabillipan 250 kv machine (Siemens Corporation,

Iselin,

New Jersey) with a two millimeter aluminum filter at a rate of 85 rads
per minute.
Cell Suspensions:

Donor animals were sacrificed by exsanguination and

the thymus and spleen were then removed, taking care to avoid any proxi¬
mal lymph nodes.

The organs were ground in tissue grinders.

The sus¬

pensions were treated with 2000 units of streptokinase and 500 units
of streptodornase per 40 cc. of suspension.

The suspension was allowed

to settle for twenty minutes at room temperature, after which the super¬
natant was decanted and then spun at 1500 RPM for ten minutes.

The cell

button was washed and respun twice at 1500 RPM for five minutes.

Medium

199 with ten units of heparin per cc. was used for resuspension.

Viable

cells were counted at the final dilution using the trypan blue dye
exclusion method.

Thymus cell suspensions were injected intravenously

at a dose of .2 to .5 cc. (within each experiment the dose was constant).
Spleen cells were delivered intraperitoneally at a dose of 1 cc.

•iM

;

■

r
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Tumor Cells:

Cells syngeneic with the

mastocytoma cells)

mouse (P-815-X2

were maintained by serial in vivo passage accord-

ing to previously described methods.

Tumor cells were obtained by

peritoneal lavage of the passage animals.

The cells were spun at

1500 RPM for five minutes, then resuspended in medium 199.

Viable

cells were counted using the trypan blue dye occlusion method.

All

injections were made intraperitoneally with 3 x 10^ cells diluted to
.5 cc.
Enumeration of tumor cells in the peritoneal cavity:

Following the

method described by Freedman et al, the mice were anesthetized with
ether, then killed by cervical dislocation.

114

The peritoneal cavity

was exposed, then injected with 5 cc. of medium 199 with ten units of
heparin per cc.

The peritoneum was vigorously massaged and then aspirated.

The peritoneum was slit open so that any remaining fluid could be drawn
up.

Cells were spun at 1500 RPM for five minutes then resuspended at

appropriate dilutions for counting.
the trypan blue dye exclusion method.

Viable cells were determined using
In the animals not treated with

immune T cells, tumor cells were easily distinguished from other peri¬
toneal cells.

When the animals were treated with the sensitized T cells,

the tumor cells were more difficult to distinguish from other cells.
Initially tumor cell counts were compared to counts made from Wright
stain smears with good correlations.
Experimental Design:

Sensitized T cells were prepared by injecting

intravenously C3H(H2K) thymus cells at different doses into lethally

r
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irradiated (850 rads) CDF^ according to the protocol in each experimental
section.

Five days post injection, the CDF^ were sacrificed and the

spleens harvested.

All nucleated cells from each spleen were counted

by the trypan blue dye exclusion method.
present in one spleen.

Usually 3-15 x 10^ cells were

The number of cells recovered from a spleen bore

no relation to the thymus cell dose used to prepare the sensitized cells.
There also was no correlation between the number of cells in a spleen
and the eventual degree of tumor suppression.

The spleens from each

thymus cell dose were prepared such that the sensitized T cells from
one spleen were diluted in 1 cc. of medium 199 with ten units of heparin
per cc.

In experimental sections III,

IV and V the sensitized T cells

were diluted according to the protocol in each section such that half,
one-quarter, or one-eighti the cells from one spleen were diluted in
1 cc. of medium 199.

All test suspensions of sensitized T cells were
z:

injected intraperitoneally at the same time as 3 x 10° P-815-X2 masto¬
cytoma cells (diluted to a standard volume of .55) into seven or eight
week old C3H(H2K) mice.

In experimental section V, the C3H(H2K) reci¬

pients either received 850 rads two hours prior to use or received no
irradiation according to the protocol.

All tumor cell recipients were

sacrificed four days after injection and the tumor cells in the peri¬
toneum were enumerated (see figure I).

21

Experimental Results:

Section I

Growth of Ascites Tumor Cells in Allogeneic and Syngeneic
Recipients

Preliminary tests confirmed the results of Freedman et al that
P-815-X2 mastocytoma cell growth was not different for the first four
days after injection into C3H(H2K), DBi^C^D), or CDF-^ normal or
lethally irradiated ( 850 rads) recipients.j^g numt,er of tumor
cells recovered four days after the injection of 3 x 10^ cells was
O

always in the range of 1 x 10

cells.

Thus it was possible to examine

the effect of syngeneic sensitized T cells on allogeneic tumor cell
growth.

Section II.

The Effect of the Number of T

Derived Lymphocytes used

for Sensitization on Tumor Cell Growth
Different doses of C3H(H2K) thymus cells were used to produce
sensitized T cells.

The sensitized T cells from the CDF]^ hosts given

different numbers of thymus cells were examined for their ability to
suppress the growth of the allogeneic tumor cells in the non-irradiated
C3H(H2K) host.

Groups of five or six lethally irradiated CDF^ received

C3H thymus cells in the following doses:
and 120 x

.

106

4 x 10^, 15 x

^, 60 x 10^,

10

On day five, the spleen cells harvested from each CDF^

were injected intraperitoneally at the same time as 3 x 10^ tumor cells
into C3H recipients such that four to six animals each received the

.0 l €
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cells from one spleen at each thymus cell dose.

Four days after the

tumor cell injection, the recipients were sacrificed and the tumor cells
in each mouse were counted.

In figure 2 the number of cells counted in

the test mice are expressed as the percentage of cells present in untreated
CgH controls.

The data in figure 2 represent a minimum of six different

experiments involving at least 25 mice at each dose except 4 x

^

10

which is represented by the mean number of tumor cells from 5 mice.
Control cells included C3H T cells injected into lethally irradiated
C3H mice.
with 3 x

The spleens from this group were harvested and injected
1()6

tumor cells into C3H recipients.

affected by these spleen cells.

Tumor growth was un¬

When untreated

irradiated CDFy spleen

cells were used tumor growth was also unaffected.

These controls were

each done on two occasions.
If each thymus cell used for sensitization acted independently
to effect tumor cell rejection, one would expect that doubling the
thymus cell dose would roughly halve the number of tumor cells re¬
maining in the host.

The data in figure 2 show that no significant

difference was present in the number of tumor cells recovered when
the thymus cell dose was increased from 15 x 10^ to 30 x 10^ or when
it was increased from 60 x

^ to 120 x

10

^.

10

An eight fold increase

in the thymus cell dose from 15 x 10^ to 120 x
suppression roughly three fold.
of tumor cells

106

increased tumor

The data indicate that the growth

is related to the number of thymus cells used to prepare
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the sensitized T cells, but not in a linear fashion.

These findings

suggest that some type of regulation occurred which either suppressed
or amplified the effects of the sensitized T cells.

Section III.

The Effect of the Number of Sensitized T Derived Lymphocytes
on Tumor Cell Growth

The following series of experiments were designed to evaluate
whether tumor suppression was related in a one-to-one fashion to the
number of sensitized T cells used in vivo as has previously been
shown by Brunner et al in vitro.

Thus different numbers of sensi¬

tized T cells from the spleens of mice given individual doses of thymus
cells were used to determine their effect on allogeneic tumor cell
rejection.
Groups of lethally irradiated CDF-^ were injected intravenously
with C3H thymus cells at four doses:
and 120 x

106

as in section II.

15 x

106,

30 x 10^, 60 x 10^,

The spleen cells were harvested on

day five and injected intraperitoneally at the same time with 3 x 10^
tumor cells such that each recipient received all the cells from one
spleen, or one-half the cells, or one-quarter the cells, or one-eighth
the cells from the CDF^ which had been injected with
cells.

120

x

10^

thymus

Four to six C3H recipients were in each experimental group.

The same protocol was followed with the sensitized T cells prepared
from the thymus cell doses of 15 x 10^, 30 x 10^, and 60 x 10^.

Each

C3H recipient was sacrificed four days after injection and the tumor
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cells were counted.

The cells counted were expressed as a percentage

of the cells present in untreated controls.

Each number in table 1 re¬

presents the mean from at least three experiments each including four
to six mice.

Clearly the sensitized T cells prepared at any of the

thymus cell doses are not related in a linear fashion to the suppression
of tumor cell growth.

Doubling or quadrupling the absolute number of

sensitized T cells prepared from the 15 x 10^ or 30 x 10^ thymus cell
dose had no significant effect on the degree of tumor cell growth.
The data indicate that the sensitized T cells must be influenced by other
factors (cellular or humoral) in effecting immunologic injury.

Section IV.

The Effect of Cortisone Sensitive Cells

The previous experiments demonstrated that the thymus cell dose
used co prepare the sensitized T cells was not related in a one-to-one
fashion to tumor kill.

Also it was shown that this deviation from a

linear relationship occurred in the efferent limb of the tumor rejection
response, though the possibility that regulation occurred in the sen¬
sitization limb was not ruled out.

The next question asked was whether

subpopulations of T cells might be interacting and thus regulating the
degree of immunologic injury.

Gershon has shown that cortisone sensitive

T cells were able to regulate the level of T cell DNA synthesis in the
spleens of mice undergoing a GVH reaction.In the following experi¬
ments the roles of cortisone sensitive and resistant T cells were evalu¬
ated in tumor allograft rejection.
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Thymus cell donor mice were treated with 2.5 mg. of cortisone
acetate ("Contone," from Merck, Sharpe, and Dome) 48 hours prior to
the harvest of thymus cells.

These cells were prepared in the same

fashion as whole thymus cells and were counted using the trypan blue
dye exclusion method.

Each thymus yielded 2 1/2 to 5% the number of

cells from the thymus of untreated animals.

As the normal role of

cortisone sensitive cells was in question, not the per cell effective¬
ness of cortisone sensitive cells versus resistant cells, the number
of cortisone resistant cells expected in a whole thymus cell yield was
considered "equivalent" to a whole thymus.

If the yield from an average

untreated thymus was 120 x 10^, the yield from the average cortisone
treated thymus was considered "equivalent" to 120 x 10^ cells.

Thus

in a particular experiment in which thirty mice were to be used as
thymus cell donors, fifteen were pretreated with cortisone.

The two

groups of thymuses were harvested and prepared in exactly the same
manner.

The final dilution was attained at which the desired number of

whole thymus cells were suspended in .3 cc of medium.
with cortisone were diluted to the same level.

The cells pretreated

Thus both groups of cell

suspensions should have had the same number of cortisone resistant
cells, but the whole thymus cell preparation had, in addition, cortisone
sensitive cells in the same proportion as found in the thymus gland.
Groups of five or six irradiated CDF^ were given whole thymus cell
doses of 15 x 10^, 30 x 10^ or 60 x 10^.

Other groups of five or six

irradiated CDF^ were given the cortisone "equivalent" dose for 15 x 10^,

c

.
-
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30 x 106, or 60 x 106 cells.
harvested.

On day five the CDF-^ spleen cells were

Each C3H recipient received 3 x 106 tumor cells injected at

the same time as either the cells from one spleen, one-half spleen, or
one-quarter spleen at the different doses of normal and cortisone
equivalent T cells.

Four days after injection the C3H were harvested

and the tumor cells were counted.

The cells were expressed as the per¬

centage of cells in C3H controls.

One such experiment is presented in

Table 2.

At the high dose the cortisone equivalent cells were five times

as effective in suppressing tumor growth as whole thymus cells.

At

the low dose the cortisone resistant cells were only one-tenth as
effective as whole thymus cells.
experiments are summarized.

In Table 3 the results from four

Each number represents the ratio of regular

thymus cells to cortisone resistant cells of the mean of the counted
cells from four to six animals expressed as the percentage of cells in
C3H controls.

(The data in Table 2 are the results from experiment

three at one spleen and are present in Table 3 as a ratio of five and
one-ninth.)

Each experiment was done comparing a high dose (60 x 10^)

of thymus cells to a cortisone equivalent dose and comparing a low dose
(15 x lO^ or 30 x

10^)

of cells to a cortisone equivalent dose.

The data demonstrated that the cortisone sensitive cells in some
manner regulated the immunologic injury effected by whole thymus cell
preparations.

The cortisone resistant cells from a high dose of cells

used for sensitization were more effective suppressing tumor growth
than the same absolute number of cortisone resistant cells in the

.j

r:'T

c
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presence of cortisone sensitive cells.

In this situation, the presence

of the cortisone sensitive cells suppressed the effect of the sensitized
T cells.

At the low dose of cells used for sensitization, the presence

of cortisone sensitive cells amplified the immunologic injury inflicted
by the sensitized T cells.

These experiments demonstrated that this re¬

gulation occurred at the efferent limb of the tumor rejection process.
The results of the sensitized T cells from one spleen prepared from the
high dose of thymus cells showed that the cortisone resistant cells
were more effective when the cortisone sensitive cells were not present.
When the absolute number of sensitized T cells was decreased by using the
cells from one-half or one-quarter spleen, the presence of the cortisone
sensitive cells increased the tumor killing.

This is demonstrated in

experiment two, Table 3, by the change in ratio from 18 when the cells
from one spleen were used to the ratio of 1/6 when one-quarter spleen
cells were used.

The data do not rule out the possibility that T cell

interactions occurred during the sensitization process.

It is important

to note that when normal whole thymus cells were diluted to the same
absolute numbers as the cortisone resistant cells (the thymus cell
dose of 4 x 10^ used in section II, Figure 2, is the same number of cells
as the cortisone equivalent dose to 60 x 10^ in Table 2) the cortisone
resistant cells were five times more effective.

■

.

£
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Section V.

The Effect of Irradiation of the Host on Tumor Killing
by Sensitized T Cells

In preceeding experiments cellular interactions were demonstrated
between cortisone resistant and sensitive populations of T cells which
lead to regulation of the sensitized T cells in the destruction of allo¬
geneic tumor cells.

It was decided to investigate next whether the

host’s cells might also be involved in interactions with sensitized
T cells.

The work of Freedman et al has isolated the T derived lympho-

cyte as being capable of working independently.

However, all their

experiments were done in heavily irradiated CgH recipients (850 rads)
given large numbers of sensitized T cells (in terms of the present ex¬
periments the number of cells would be equivalent to the cells from
two or three spleens).

A dose of 50 x

prepare the sensitized T cells.

10 ^

thymus cells were used to

This high cell dose suppressed tumor

growth completely and might well have obscured any regulatory effect
mediated by the host.

The irradiation of the test recipients would be

sufficient to kill all the host cells usually involved in immunologic
processes except the macrophages.
To examine the possible role of host cells, sensitized T cells
were prepared in the usual manner and were then injected with 3 x 10
tumor cells in either normal C3H recipients or CgH recipients which had
received 850 rads two hours prior to injection.

Three experiments

were done using only a high thymus cell dose (60 x

10^

and three experiments were done with both a high (60 x

or greater)
10^

or greater)
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and a low thymus cell dose (15 x 10^ or 30 x 10^).
is presented in Table 4.

One such experiment

The degree of tumor killing in the normal

C3H recipients at the high and low dose was the same, a result consistent
with the dose response curve reported earlier in this study.

In the

irradiated recipients the high cell dose was significantly more effective
suppressing tumor growth, while at the low dose the cells were signi¬
ficantly less effective.
in Table 5.

The data from six experiments are summarized

The results are presented as the ratio between normal and

irradiated recipients of the mean number of tumor cells counted, expressed
as the percentage of cells present in C^H controls.

Thus the data from

Table 4 are expressed as a ratio of 1/5 at the low dose and a ratio of
4 at the high dose in Table 5.

These results demonstrated that the host

did interact with the syngeneic sensitized T cells and that this inter¬
action was part of the regulation of the sensitized T cell effect.
Irradiation most likely eliminated a radiosensitive cell which was in¬
volved in suppressing and amplifying the immune response against the
allogeneic tumor cells.
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Discussion

These experiments were designed to evaluate the possibility that
T cell activity in a tumor allograft rejection system was subject to
regulation.

The results indicated that regulatory mechanisms do exist,

that they are demonstrable between subpopulations of T cells in the
effector limb of the rejection process, and that one of the mechanisms
involves a radiosensitive host cell.
Studies were undertaken to determine whether the relationship
between the dose of thymus cells and the degree of tumor suppression was
a first order reaction.

In enzyme kinetic studies, the investigator

can measure the amount of each reactant and the final product, and
then draw conclusions regarding the product as a function of the amount
of reactants and the interactions between them.

The results can be inter¬

preted to show whether the reaction is zero order, in which the product
is independent of any variable; first order, in which the product is
formed in a linear relationship to one reactant; second order,

in which

the product is a function of two reactants and is proportional to the
square of the varied reactant; or

order, in which the product is a

function of N reactants and is proportional to the varied reactant
raised to the

power.

In the experiments presented in section II,

the number of tumor cells was kept constant while the dose of thymus
cells used to prepare the sensitized T cells was varied.

If a first
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order reaction was present,doubling the number of thymus cells should
have doubled the degree of tumor suppression.

This did not occur,

though it was clear from the dose response curve in figure 2 that the
thymus cell doses used were not at either extreme of the curve where
such a relationship might not be evident.

Taub and colleagues have

shown that the localization of T cells to mice spleens increased pro¬
portionally as the cell dose was increased (from 10^ to 10^).^^

Thus

the results of these experiments are not due to variable homing of the
different doses of thymus cells.

Moreover, previous investigators have

shown that lethally irradiated mice can be reconstituted with increasing
doses of thymocytes (in the same dose range as these experiments) with a
result of an increasing DNA synthetic response to an antigenic stimulus.

119

The mice spleens thus do have the room for these doses of thymus cells
to react immunologically.

The results in Table 4 also indicated that

the same dose of thymus cells is capable of a greater immunologic response
if a regulator influence is eliminated.
be interpreted as indicating a suppressed

Thus the curve in Figure 2 can
order reaction in which an

unknown number of cells are involved in regulating the immunologic
response.
Perhaps more to the point are the experiments from Section III
in which a fourfold increase in the absolute number of sensitized T
cells injected into the test animals did not significantly effect the
degree of tumor suppression.

Since only the sensitized T cells were

being varied these experiments demonstrated that cellular interactions
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occurred in the efferent limb of the tumor allograft rejection process.
As in the preceeding experiments, this lack of a linear response to in¬
creasing doses of cells indicated that a suppressive interaction was
occurring.

These findings do not preclude the possibility that cellular

interactions also occurred during the sensitization phase.

Gershon's

studies of the cell kinetics in the GVH reaction also demonstrated a
suppressed

order reaction, but the assay of the DNA synthesis of

donor T cells in the F-^ spleen may reflect interactions during T cell

.

.

.

sensitization.
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The data concerning tumor cell killing in the irradiated host are
particularly interesting.

Though the degree of tumor suppression was

unaffected by quadrupling the number of thymocytes delivered to the
normal host, the same thymocytes delivered to an irradiated animal
reacted quite differently (see Tables 4 and 5).

At high doses the

immune cells were much more effective suppressing tumor growth in the
irradiated animals, and at low doses they were much less effective.
Irradiation of the host appeared to eliminate a radiosensitive factor
(cell) which was involved in suppressing or amplifying the action of
immune T cells.
These results may explain the "Celada effect".

Celada noted that

when presensitized syngeneic T cells were injected in a host, they did
not produce antibody upon antigenic stimulus unless the host was lethally
irradiated.
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In these experiments, irradiation may have eliminated

host cells which were suppressing the presensitized antibody producing cells.

-

•
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In studies of cortisone sensitive and resistant T lymphocytes (Tables
2 and 3) a similar type of regulation was demonstrated.

When cortisone

sensitive cells were eliminated, the cortisone resistant cells were more
effective tumor killers at a high dose, and less effective at a low dose.
These experiments showed that cortisone sensitive cells were involved
in both suppressing and amplifying the effects of immune T cells.

When

the efferent limb of the tumor rejection process was isolated, the corti¬
sone sensitive cells were again shown to be suppressing or amplifying
the effect of the sensitized T cells.

These experiments do not indicate

whether the regulatory effects of the cortisone sensitive cells were
confined to the efferent limb of the tumor rejection reaction, or were
also present in the afferent limb.
T cells harvested from the

If the absolute number of sensitized

spleens were known, the effect of the

cortisone sensitive cells during sensitization might be clear.
nucleated cells harvested from the

All the

spleens were counted; however,

there was no way of distinguishing the F^ host cells from the C3H T
cells.

Moreover, if these allogenic cells were separated by appropriate

antiserum, there is no way presently of distinguishing which C3H T cells
were sensitized and which were not.

These experiments demonstrated that

cortisone sensitive T cells were involved in a regulatory role and cor¬
roborate the evidence in sections II and III that T cell interactions
occurred in the rejection of allogenic tumor cells.
Davies and colleagues have shown that T cells can increase the
number of B cells producing antibody to certain antigens.
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Gershon’s
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group has shown that T cells also can suppress antibody producing B
cells.-*-23

The t cell thus appears to play a major role in the control

of humoral immunity.

The experiments presented in this thesis showed

that T cells may also play a significant role in the control of tumor
allograft rejection, and that a non-sensitized radiosensitive cell is
probably involved in such controls.

The regulation by the cortisone

sensitive cell in the efferent limb of the tumor allograft rejection
process is quite similar to the role played by the radiosensitive host
cell, in that both are involved in amplifying and suppressing the effects
of sensitized T cells.

The data do not permit any conclusions that these

processes are related.

But one can hypothesize that the cortisone

sensitive cell modifies the action of the sensitized T cells by inter¬
acting with a radiosensitive cell.

This hypothesis is consistent with

the findings of investigators that subpopulations of T cells and BMD
cells synergize in the GVH reaction.

124—125

This type of model might

be analogous to feedback inhibition systems demonstrable in enzyme re¬
actions and other biological processes.

Such a system merges the differ¬

ences apparent in cellular and humoral immunity.

It would be fascinating

to know whether the T cells which regulate the B cell antibody response
are cortisone sensitive.

If this were the case, the whole array of

immune responses might well be under the regulation of a population of
"master T cells" permitting fine control with great biological economy.

.
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FIGURE I

Experimental Design

p|Pi
Day I

Day 9

Day I:

Thymus ceils harvested from C3H (H2K) are injected in- ,
travenously into iethally irradiated CDF| (in Freedman's
system, into D8A9 (H2D)).

Day 5: Spleens harvested from CDF are injected with P-815-X2
mastocytoma cells from passage animal into C3H (K2K)
(in experimental section 5 half the test recipients were
irradiated).
Day 9: The tumor cells in each test animal are counted.
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FIGURE 2

The Relationship of Thymus Ceil Dose
to Tumor Suppression

80 i 8.9
Each number represents a minimum of

,

six experiments involving at least 25 mice

g

at each dose except 4x!0 which represents
the resuits of 5 mice.

Each number is the

mean tumor cells counted expressed as the
percentage of cells present in untreated
C^H controls.
P value comparing 120 Gnd 60 to 30 and
15 less than 0.01
P value comparing 120 or 60 to 30 or
'

15 less than 0.01

28.9 i 6.6
„

24 ± 4.9

13.8 A 2.2

10.8 L 2.2

10

20

30

40

50
60
70
80
Thymus Cell Dosage

90
100
(x 10 j

110

120
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TABLE I

The Relationship of Sensitized T Cells
to Tumor Suppression

T Cell Dosage
(x I06 )

I Spleen
X

1/4 Spleen

1/8 Spleen

X| 1.9 sem 5.7

30.5 sem 10

X

13.8 sem 2.3

120

1/2 Spleen

9.0 sem 3.9

x
60

10.8

sem

sem 8.3

24 sem 5.8

30

24

sem 4.9

23.3 sem 5.3

24.9 sem 8.1

15

29

sem

32

2.2

6.6

26

sem 9.1

Each number represents the mean tumor cells
counted from three experiments each including
four to six mice expressed as the percentage of
cells present in untreated C3H controls.
Each starred value (x) is p less than 0.05 when
compared to unslcrred.

■\

■
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TABLE 2

The Effect of Cortisone Resistant T Ceils
Compared to Cortisone Resistant and Sensitive
T Cells
Dosage of
T Cells (x 10s)

Mean

SEM

30

99

5.5

30

92.6

7.3

60

12.5

60

2.6

"cortisone
equivalent"

2.1

"cortisone
equivalent"

0.49

Each number represents the rn^an tumor cells from
4 to

6

mice expressed cs the percentage of cells

present in C^H controls.
(a) p less than O.OI when whole thymus cells
compared to cortisone equivalent doss for
both dosages
(b) when cortisone equivalent 30 compared to
cortisone equivalent 60, p less than
(c)

0.001

the two regular thymus cell doses are not
different significantly

,

'
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TABLE 3

The Relationship between Cortisone
Resistant and Sensitive Cells as the
Number of Sensitized Cells is Decreased

c

Thymus dose:
Exper. no.

c

greater than 60 x 10^
I Spleen

1/2 Spleen

less than 60 x 10
1/4 Spleen

I Spleen

1

i

1/2 Spleen

1/2

2

18

6

1/6

1/3

2/3

3

5

3

1/2

1/9

1

4

4

1

1/2

1

Numbers expressed as the ratio of the mean
percentage tumor survival of cortisone sensitive
and resistant cells compared to the mean per¬
centage tumor survival of cortisone resistant
cells
I spleen and 1/2 spleen of greater than 60 x 10

is different at the p less than 0.01 level from
the less than 60x10^ I spleen and 1/2 spleen
t test done on log values

g
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TABLE 4

Tumor Growth Suppression in the
Irradiated and Non-irradiated Test Animal
Dosage of
T Cells (x 10s)

Radiated
Recipient

SEM

120

2.3

0.45

120

0.B6

0.27

30

2.4

1.0

30

11.4

2.3

Radiated
Recipient

Mean

Each number represents the mean tumor cells from
4 to 6 mice expressed as the percentage of cells
in untreated C3H controls.
e

(a)

Radiated recipients receiving 120x10

com¬

pared to 30 x10s were different to p less
than 0.02
(b)

120

x

s is not significantly different from

10

30 x I06
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TABLE 5

The Effect of irradiation of the Test
Animal on Sensitized T Cell Activity

High Dose T Cells
Exper. no.

! Spleen

1/2 Spleen

Low Dose T Cells
I Spleen

1

2

2/3

2

1/5

1/3

3

4

4

4

8

5

8

6

5

1/2 Spleen

1/5

Each number is expressed as the ratio of
the mean percentage survival from 4 to 6
non-irradisted mice compared to the mean
percentage tumor survival from 4 to 6 ir¬
radiated mice.
The high dose effect is statistically dif¬
ferent from the low dose effect to p less
than O.OI level.

1/6
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